Article Overview

This article covers CPT coding guidance for tissue in situ hybridization testing in a pathology context, including how it relates to HER-2/neu cancer workups and how it differs from cytogenetics and molecular cytogenetics reporting. It is useful for pathologists, pathology coders, and laboratory billing staff who need to understand which CPT code family applies when interpretation and reporting are involved.